Dublin, March 09, 2022 (GLOBE NEWSWIRE) -- The "Global Cancer Pain Market, By Drug Type, By Disease Indication, Estimation & Forecast, 2017 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global cancer pain market accounted for a market size of USD 6,716.2 Million in 2021 and is projected to reach USD 9,951.2 Million by 2030, at a growth rate of 4.6% during the forecast period.
The global cancer pain market is expected to grow owing to various factors such as the niche penetration of healthcare facilities for cancer diagnostics coupled with the rising healthcare expenditure & government support worldwide. Furthermore, growing prevalence of cancer pain is also estimated to boost the market growth. According to the National Cancer Institute, as of December 2021, around 20-50% cancer patients suffer from pain.
Also, according to the Centers for Disease Control and Prevention (CDC), roughly 15.5 million cancer survivors (those who have had a cancer diagnosis) were alive in the United States in 2016, with that figure predicted to rise to over 20 million by 2026. Despite the driving factors, accessibility to facilities and high cost of treatment are expected to hinder the market growth during the forecast period.
Growth Influencers:
Rising healthcare expenditure and government support worldwide
With the growing prevalence of cancer, the awareness for the disease as well as the associated pain is also increasing. This is also leading to the rising healthcare expenditure for diagnosis and treatment of the cancer associated pain. According to the OECD, the preliminary estimates of healthcare spending for a group of 16 OECD countries jumped to about 9.9% of GDP in 2020. Therefore, the rising healthcare expenditure and government support worldwide is anticipated to fuel the market growth.
Competitive Landscape
Key players operating in the global cancer pain market include Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., Roche Holding AG, and Other Prominent Players. The cumulative market share of 4 major players is near about 35%.
These market players are involved in collaborations, mergers & acquisitions, and new product launches to strengthen their market presence. For instance, in December 2021, Pfizer collaborated with Amazon Web Services, Inc. (AWS) for creating cloud-based solutions for improving the development, manufacturing, and distribution of medicines for clinical trials testing. The company enhanced the company's position in the market.
Marketed and Emerging Drugs
There are many marketed drugs in the market by various companies. For instance, ULTRAM (tramadol hydrochloride) by Janssen Ortho, LLC; Hydromorphone Hydrochrloride by Janssen Korea, Ltd, Oxycodone by Taiwan Mundipharma Pharmaceuticals Ltd, and Lazanda (Fentanyl) by Insys Therapeutics, Inc., among others.
Many market players are also investing in various research and development activities for development of more effective drugs for the treatment of cancer pain. Some of the emerging drugs include Morphine sulfate by Tetra Biopharma/Cognitive Research Corporatio, Resiniferatoxin by Sorrento Therapeutics, Inc., and Pregabalin by Institut Cancerologie de l'Ouest/Grunenthal GmbH. Sorrento's resiniferatoxin received FDA clearance for proceeding with its Phase 2 clinical study for using epidural resiniferatoxin for treatment of intractable pain associated with advanced cancer.
The global Cancer pain market report provides insights on the below pointers:
- Market Penetration: Provides comprehensive information on the market offered by the prominent players
- Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
- Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the global cancer pain market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
- Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
- Cancer Market Growth Forecast (USD Million), 2017-2030
- Epidemiology & Patient Population; 8MM Incident Patient Population of Cancer Pain
- Country Wise Epidemiology of Cancer Pain: U.S., EU5 (Germany, France, Italy, Spain, and the UK), Japan, China, and India
- Treatment & Management of Cancer Pain: Treatment Guidelines, WHO Guidelines for Cancer Pain Management. ESMO Guidelines for Cancer Pain Management
- Marketed Drugs: ULTRAM (Tramadol Hydrochloride)-Janssen Ortho, LLC - Product Description, Other Development Activities, Clinical Development, Clinical Trials Information, Safety & Efficacy, Product Profile; Hydromorphone Hydrochloride (HCl)-Janssen Korea, Ltd; Oxycodone-Taiwan Mundipharma Pharmaceuticals Ltd; Lazanda (Fentanyl)-Insys Therapeutics, Inc.
- Emerging Drugs: Morphine Sulfate-Tetra Biopharma/Cognitive Research Corporation-Product Description, Regulatory Milestones, Clinical Development, Ongoing Current Pipeline Activity, Safety & Efficacy, product Profile; Resiniferatoxin-Sorrento Therapeutics, Inc.; Pregabalin-Institut Cancerologie de I'Quest/Grunenthal GmbH
The global Cancer pain market report answers questions such as:
- What is the market size and forecast of the Global Cancer pain Market?
- What are the inhibiting factors and impact of COVID-19 on the Global Cancer pain Market during the assessment period?
- Which are the products/segments/applications/areas to invest in over the assessment period in the Global Cancer pain Market?
- What is the competitive strategic window for opportunities in the Global Cancer pain Market?
- What are the technology trends and regulatory frameworks in the Global Cancer pain Market?
- What is the market share of the leading players in the Global Cancer pain Market?
- What modes and strategic moves are considered favorable for entering the Global Cancer pain Market?
Key Topics Covered:
Chapter 1. Research Framework
Chapter 2. Executive Summary: Global Cancer Pain Market
Chapter 3. Introduction
3.1. Cancer Market Growth Forecast (US$ Mn), 2017 - 2030
3.2. PEST (Political, Economic, Social, Technological) Analysis
Chapter 4. Global Cancer Pain Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.2. Manufacturers
4.1.3. Distributor
4.1.4. End Users
4.2. Porter's Five Forces Analysis
4.3. Market Dynamics
4.3.1. Key Trends
4.3.2. Growth Drivers
4.3.3. Challenges/ Restraints
4.4. Market Opportunity Assessment
4.4.1. Activity Mapping of Top Players (Ansoff's Matrix)
4.5. Market Growth and Outlook
4.5.1. Market Growth Forecast (US$ Mn), 2017-2030
4.5.1.1. ASTUTE Analysis
4.5.1.2. Optimistic Outlook
4.5.1.3. Reserved Outlook
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.6.1. Growth Trend Shift Analysis
4.6.2. Industry Best Practices
4.7. Epidemiology and Patient Population
4.7.1. Key Findings
4.7.2. Epidem and Market Methodology
4.7.3. 8MM Incident Patient Population of Cancer Pain
4.8. Country Wise-Epidemiology of Cancer Pain
4.8.1. United States Epidemiology
4.8.2. EU5 Epidemiology
4.8.3. Japan Epidemiology
4.8.4. China Epidemiology
4.8.5. India Epidemiology
4.8.6. Treatment and Management of Cancer Pain
4.8.7. Unmet Needs
4.8.8. Marketed Drugs
4.8.8.1. ULTRAM (tramadol hydrochloride): Janssen Ortho, LLC
4.8.8.1.1. Product Description
4.8.8.1.2. Regulatory Milestones
4.8.8.1.3. Clinical Development
4.8.8.1.4. Ongoing Current Pipeline Activity
4.8.8.1.5. Safety and efficacy
4.8.8.1.6. Product Profile
4.8.8.2. Hydromorphone Hydrochloride (HCI): Janssen Korea, Ltd.
4.8.8.3. Oxycodone: Taiwan Mundipharma Pharmaceuticals Ltd.
4.8.8.4. Lazanda (Fentanyl):Insys Therapeutics, Inc.
4.8.9. Emerging Drugs
4.8.9.1. Morphine Sulfate: Tetra Bio-Pharma/Cognitive Research Corporation
4.8.9.1.1. Product Description
4.8.9.1.2. Other Development Activities
4.8.9.1.3. Clinical Development
4.8.9.1.4. Clinical Trials Information
4.8.9.1.5. Safety and Efficacy
4.8.9.1.6. Product Profile
4.8.9.2. NanaBis: Medlab Clinical/George Clinical Pty Ltd & WriteSource Medical Pty Ltd
4.8.9.3. Resiniferatoxin: Sorrento Therapeutics, Inc.
4.8.9.4. Pregabalin: Institut Cancerologie de l'Ouest/Grunenthal GmbH
Chapter 5. Competition Dashboard
5.1. Market Concentration Rate
5.2. Company Market Share Analysis (Value %), 2019
5.3. Competitor Benchmarking
Chapter 6. Global Cancer Pain Market Analysis, By Drug Type
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
6.2.1. Opioids/Narcotics
6.2.1.1. Morphine
6.2.1.2. Fentanyl
6.2.1.3. Others
6.2.2. Non-Opioids
6.2.2.1. Acetaminophen
6.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
6.2.3. Nerve Blocks
Chapter 7. Global Cancer Pain Market Analysis, By Disease Indication
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
7.2.1. Lung Cancer
7.2.2. Colorectal Cancer
7.2.3. Breast Cancer
7.2.4. Prostate Cancer
7.2.5. Blood Cancer
7.2.6. Others
Chapter 8. Global Cancer Pain Market Analysis, By Region/Country
Chapter 9. North America Cancer Pain Market Analysis
Chapter 10. Europe Cancer Pain Market Analysis
Chapter 11. Asia Pacific Cancer Pain Market Analysis
Chapter 12. Middle East & Africa Cancer Pain Market Analysis
Chapter 13. South America Cancer Pain Market Analysis
Chapter 14. The US Cancer Pain Market Analysis
Chapter 15. The UK Cancer Pain Market Analysis
Chapter 16. Germany Cancer Pain Market Analysis
Chapter 17. France Cancer Pain Market Analysis
Chapter 18. Italy Cancer Pain Market Analysis
Chapter 19. Spain Cancer Pain Market Analysis
Chapter 20. China Cancer Pain Market Analysis
Chapter 21. Japan Cancer Pain Market Analysis
Chapter 22. India Cancer Pain Market Analysis
Chapter 23. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
23.1. Aoxing Pharmaceutical Company, Inc.
23.2. BioDelivery Sciences International, Inc.
23.3. CK Life Sciences (WEX Pharmaceuticals)
23.4. Daiichi Sankyo Co., Ltd.
23.5. Hisamitsu Pharmaceutical Co., Inc.
23.6. Mundipharma International Limited
23.7. Orexo AB
23.8. Pfizer Inc.
23.9. Teva Pharmaceutical Industries Limited
23.10. Roche Holding AG
23.11. Other Prominent Players
For more information about this report visit https://www.researchandmarkets.com/r/ouxrwr
Attachment
